03.05.2013 - Paris-based developer of non-viral gene therapy for ocular diseases Eyevensys SA has named Dr. Ivan Cohen-Tanugi as its new CEO.
Cohen-Tanugi brings the company more than 20 years of experience in the international pharmaceutical industry. He will prepare Eyevensys to launch clinical trials for the company's non-viral gene therapy products in two ophthalmic indications - uveitis and age-related macular degeneration - within the next 18 months. Cohen-Tanugi has considerable experience in biologics and in the pharmaceutical industry at an international level, notably in the fields of sales and marketing, global product launches, R&D team leadership and financing. The physician and MBA joins Eyevensys from Teva Pharmaceuticals, where he was Vice President and General Manager of the US Biologics and Specialty unit. Cohen-Tanugi began his career at Sanofi, then worked for many years with Roche Pharma in Basel. Prior to his activities at Teva, he was employed with Amgen International.http://www.european-biotechnology-news.com/people/bio-people/2013-01/ivan-cohen-tanugi.html